DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling

被引:46
作者
Wu, Kaijie [1 ]
Wang, Bin [1 ]
Chen, Yule [1 ]
Zhou, Jiancheng [1 ]
Huang, Jun [1 ]
Hui, Ke [1 ]
Zeng, Jin [1 ]
Zhu, Jianning [1 ]
Zhang, Kai [1 ]
Li, Lei [1 ]
Guo, Peng [1 ]
Wang, Xinyang [1 ]
Hsieh, Jer-Tsong [2 ]
He, Dalin [1 ]
Fan, Jinhai [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Urol, Xian 710061, Peoples R China
[2] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
基金
中国国家自然科学基金;
关键词
Bladder cancer; Pirarubicin; Tumor recurrence; DAB2IP; Twist1; P-glycoprotein; ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; PROSTATE-CANCER; MESENCHYMAL TRANSITION; CELL CARCINOMAS; DOWN-REGULATION; EXPRESSION; RESISTANCE; GROWTH; PROLIFERATION;
D O I
10.1016/j.cellsig.2015.09.014
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
There is a high frequency of tumor recurrence in non-muscle invasive bladder cancer (NMIBC) after transurethral resection and postoperative intravesical chemotherapy, however, the molecular mechanisms leading to the chemoresistance and tumor re-growth remain largely unknown. In this study, we observed a significant decrease of DAB2IP expression in high-grade and recurrent NMIBC specimens, which was negatively correlated with Twist1 expression and predicted a lower recurrence-free survival of patients. Mechanistically, DAB2IP could inhibit the phosphorylation and transactivation of STAT3, and then subsequently suppress the expression of Twist1 and its target gene P-glycoprotein, both of which were crucial for the pirarubicin chemoresistance and tumor re-growth of bladder cancer cells. Overall, this study reveals a new promising biomarker modulating the chemoresistance and tumor recurrence of NMIBC after bladder preservation surgery. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:2515 / 2523
页数:9
相关论文
共 43 条
[11]   Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy [J].
Choi, Woonyoung ;
Porten, Sima ;
Kim, Seungchan ;
Willis, Daniel ;
Plimack, Elizabeth R. ;
Hoffman-Censits, Jean ;
Roth, Beat ;
Cheng, Tiewei ;
Mai Tran ;
Lee, I-Ling ;
Melquist, Jonathan ;
Bondaruk, Jolanta ;
Majewski, Tadeusz ;
Zhang, Shizhen ;
Pretzsch, Shanna ;
Baggerly, Keith ;
Siefker-Radtke, Arlene ;
Czerniak, Bogdan ;
Dinney, Colin P. N. ;
McConkey, David J. .
CANCER CELL, 2014, 25 (02) :152-165
[12]   In vivo inhibition of lung cancer by GRN163L:: A novel human telomerase inhibitor [J].
Dikmen, ZG ;
Gellert, GC ;
Jackson, S ;
Gryaznov, S ;
Tressler, R ;
Dogan, P ;
Wright, WE ;
Shay, JW .
CANCER RESEARCH, 2005, 65 (17) :7866-7873
[13]   Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer [J].
Dote, H ;
Toyooka, S ;
Tsukuda, K ;
Yano, M ;
Ouchida, M ;
Doihara, H ;
Suzuki, M ;
Chen, H ;
Hsieh, JT ;
Gazdar, AF ;
Shimizu, N .
CLINICAL CANCER RESEARCH, 2004, 10 (06) :2082-2089
[14]   Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour [J].
Dote, H ;
Toyooka, S ;
Tsukuda, K ;
Yano, M ;
Ota, T ;
Murakami, M ;
Naito, M ;
Toyota, M ;
Gazdar, AF ;
Shimizu, N .
BRITISH JOURNAL OF CANCER, 2005, 92 (06) :1117-1125
[15]   Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS [J].
Duan, Yi-Fan ;
Li, Dong-Feng ;
Liu, Yan-Hui ;
Mei, Ping ;
Qin, Yu-Xuan ;
Li, Liang-Fang ;
Lin, Qiu-Xiong ;
Li, Zi-Jun .
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2013, 12 (02) :204-209
[16]   Cathepsin E, Maspin, Plk1, and Survivin Are Promising Prognostic Protein Markers for Progression in Non-Muscle Invasive Bladder Cancer [J].
Fristrup, Niels ;
Ulhoi, Benedicte P. ;
Birkenkamp-Demtroder, Karin ;
Mansilla, Francisco ;
Sanchez-Carbayo, Marta ;
Segersten, Ulrika ;
Malmstrom, Per-Uno ;
Hartmann, Arndt ;
Palou, Joan ;
Alvarez-Mugica, Miguel ;
Zieger, Karsten ;
Borre, Michael ;
Orntoft, Torben F. ;
Dyrskjot, Lars .
AMERICAN JOURNAL OF PATHOLOGY, 2012, 180 (05) :1824-1834
[17]   EXPRESSION OF MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP), MDR1 AND DNA TOPOISOMERASE-II IN HUMAN MULTIDRUG-RESISTANT BLADDER-CANCER CELL-LINES [J].
HASEGAWA, S ;
ABE, T ;
NAITO, S ;
KOTOH, S ;
KUMAZAWA, J ;
HIPFNER, DR ;
DEELEY, RG ;
COLE, SPC ;
KUWANO, M .
BRITISH JOURNAL OF CANCER, 1995, 71 (05) :907-913
[18]   MDR1 and ERCC1 Expression Predict Outcome of Patients with Locally Advanced Bladder Cancer Receiving Adjuvant Chemotherapy [J].
Hoffmann, Andreas-Claudius ;
Wild, Peter ;
Leicht, Christina ;
Bertz, Simone ;
Danenberg, Kathleen D. ;
Danenberg, Peter V. ;
Stoehr, Robert ;
Stoeckle, Michael ;
Lehmann, Jan ;
Schuler, Martin ;
Hartmann, Arndt .
NEOPLASIA, 2010, 12 (08) :628-636
[19]   Cancer statistics, 2007 [J].
Jemal, Ahmedin ;
Siegel, Rebecca ;
Ward, Elizabeth ;
Murray, Taylor ;
Xu, Jiaquan ;
Thun, Michael J. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66
[20]   Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer [J].
Kim, Wun-Jae ;
Kim, Eun-Jung ;
Kim, Seon-Kyu ;
Kim, Yong-June ;
Ha, Yun-Sok ;
Jeong, Pildu ;
Kim, Min-Ju ;
Yun, Seok-Joong ;
Lee, Keon Myung ;
Moon, Sung-Kwon ;
Lee, Sang-Cheol ;
Cha, Eun-Jong ;
Bae, Suk-Chul .
MOLECULAR CANCER, 2010, 9